Ameano Peptides (.com)
ameanopeptides.com
Email me when this record changes
Following this record emails you when it gains a dated entry or its published claims are re-read, and nothing about any other supplier. No topic below is ticked: tick one only if you also want it in the same email.
Compiled automatically from the dated observations in this vendor's record. How we evaluate.
Never merged into one number. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
Ameano Peptides' own two surfaces disagree about the same laboratory report: the product-page certificate for batch AMP-3P1006202026-03 shows a single finding, 11.75 mg and 99.681 percent, with no method named on the document face, while the vendor's own testing portal for that identical task number and analysis date shows three vials, that same 99.681 percent figure plus two others, 99.318 percent and 99.368 percent, that the product page omits. The site otherwise publishes per-batch Janoshik reports with unique verify keys alongside a testing portal where that June batch's panel is the only four-assay panel opened, sterility, endotoxin, and heavy metals included, the other populated panels carrying one assay each, and two of the three published retatrutide reports matched their laboratory-hosted copies exactly on the first read, though that same verification path returned a Cloudflare challenge instead of a match on the later re-check. A reader who has pulled a certificate directly from the portal for a current batch could say whether the product-page image still shows one vial's figure where the portal shows three.
What the record holds
SAME OR NEXT DAY
“the About page claims same-day dispatch on qualifying orders”
free shipping over $200; Shipping Insurance sold separately as $4.99 line item; qualifying orders undefined, no cutoff time stated; dedicated shipping-and-delivery-policy page 404s
Read from this supplier's own pages on 2026-08-25. This publication has never placed an order with any supplier. This row records what is written and measures nothing about what actually happens after an order.
$78.00
Compound retatrutide 10mg
Listed as AMP-3P 10mg, SKU AMP-3p1004012026-02; the storefront calls it a triple-agonist and the lab report names it Retatrutide
Price as recorded $78.00
Read on 2026-08-25. One reading on one day, and prices are not tracked over time here.
This supplier was not part of the Trustpilot reading of 2026-08-25, which covered 59 of the 126 suppliers on file. That is a fact about this publication's coverage, stated rather than left to be read either way.
12 claims from this publication's own dossier on this supplier were read again against the live site on 2026-08-25: 0 held, 12 corrected before publication.
A corrected claim is an error of ours that the re-read caught before it reached a page. This line tracks this publication's own accuracy. It says nothing about the supplier.
Dated entries
4 observations on file, recorded 2026-08-25. Newest first, appended and never rewritten.
Certificates are published, batch-specific, from a named lab, and built to be independently verifiable, which by design is the strongest documentation chain in this batch of eight. Whether that verification half still completes for a reader is a separate question, taken up below. A site-wide index at /coa carries 68 entries against a 78-item catalog, 7 of the 68 opening a product photograph rather than a certificate, so 61 of the 78 items reach a laboratory report from the index, and five research peptides in the live catalog have no index entry at all. Product pages carry both the current report and dated prior batches. The laboratory is Janoshik Analytical, and on the product pages every report links to verify.janoshik.com under its own unique key. That pairing is a product-page feature and not a site-wide one: those 68 index entries carry zero verification hrefs, and one BPC-157 batch (BPC1002112026-19) links to the bare laboratory host with no report image hosted on the vendor site. On AMP-3P 10mg the three published reports are task #194694, batch AMP-3P1006202026-03, verify key JSH1BDD3NZ49, testing ordered 12 JUN 2026, sample received 16 JUN, analysis conducted 24 JUN 2026; task #147744, batch AMP-3P1004012026-02, key LCMQL7NAJ4KZ, analysis 14 APR 2026, Retatrutide 11.14 mg, 11.46 mg and 11.03 mg with purity 99.909%, 99.879% and 99.919% across three vials; and task #124207, batch AMP-3P1003122026-01, key DPC3CJE9QN9Z, analysis 23 MAR 2026, Retatrutide 11.55 mg, 11.44 mg and 11.39 mg with purity 99.741%, 99.725% and 99.732%. The tests requested line on the two later reports reads "Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide)", and the finding line names Retatrutide, which is how the house code AMP-3P resolves. I verified two of these against the laboratory rather than the vendor: for tasks #124207 and #147744 the image served by verify.janoshik.com under the vendor's own key carries identical task numbers, batches, dates, masses and purities to the copy hosted on ameanopeptides.com. That check is stamped to the 2026-08-25 read rather than recorded as a standing property, and on re-check it did not reproduce: all three verify.janoshik.com URLs answered HTTP 403 behind a Cloudflare challenge, and the vendor portal points instead at the bare laboratory host, whose HTTPS endpoint does not complete a TLS handshake at apex or www. Neither verification path the vendor publishes completes for a plain client at the later read. The vendor also runs its own testing portal, and the portal page for batch AMP-3P1006202026-03 publishes a four-assay panel: mass and purity, task #194694, key JSH1BDD3NZ49, dated 24 JUN 2026; sterility, task #194697, dated 07 JUL 2026, key M5D6U8WNDXT6, with TAMC and TYMC both marked PASS; endotoxin, task #194700, dated 24 JUN 2026, key TRDN9PPZF21H, reading under 1 EU/Vial; and heavy metals, task #194703, dated 23 JUN 2026, key HK5DZI5JQWYA, with arsenic, cadmium and lead recorded as not detected. The sterility, endotoxin and heavy-metal figures are published only on that host, not on the storefront and not on the /coa index.
Recorded prices, read from the WooCommerce Store API and confirmed on the product pages: AMP-3P 6mg $53.00, 10mg $78.00, 12mg $82.00, 20mg $108.00, 24mg $118.00, 48mg $215.00, with a bulk table on the 10mg page of 10 percent off at five to nine units ($70.20) and 15 percent at ten or more ($66.30); BPC-157 10mg $44.00; Reta/Cagri Blend 12.5mg/2.5mg $135.00; Survodutide 10mg $95.00; Cagrilintide 5mg $49.00 and 10mg $88.00; Tesamorelin 10mg $68.00; AMP-2P 10mg $53.00 rising to 60mg $168.00. There is no standalone BPC-157 5mg. The catalog held 78 items today and includes topical cosmetic formulations and lab accessories alongside the peptides. Published policy: free shipping over $200, with Shipping Insurance sold separately as a $4.99 line item; the About page claims same-day dispatch on qualifying orders. Payment gateways, read from the cart's own state without transacting, are three: imerchant_nmi, linkmoney, and btcpaygf_default, and product pages advertise "Pay with Crypto, Save 10%". Storage guidance is specific and per-product: below 8 C dry before reconstitution, 2 to 8 C after and used within 30 days, minus 20 C for long-term with freeze-thaw cycles avoided. Research-use-only language is thorough: a 21-or-over interstitial whose attestation reads that products "are provided for laboratory research use only and are not intended for use in or on humans or animals", a per-product notice, and a footer disclaimer including 503A and 503B non-facility language. The entity is published as Ameano Peptides LLC, 11323 Arcade Dr. STE 105, Little Rock, AR 72212, phone +1 877 312 1560.
CAUTIONCautions noted. First, two surfaces the vendor itself publishes disagree on task #194694, and the disagreement is vendor against vendor rather than vendor against Janoshik. The product-page PNG shows a single finding row, Retatrutide 11.75 mg with a purity line reading 99.681% and no analytical method named on the report face. The vendor's own portal page for batch AMP-3P1006202026-03 shows three vials, 11.75 mg, 11.83 mg and 11.68 mg, with purity lines reading 99.681%, 99.318% and 99.368% and again no method named, under the same task number, the same key JSH1BDD3NZ49 and the same analysis date of 24 JUN 2026. The product page therefore carries the highest of the three purity figures and omits the other two. The two older reports on the same product match their laboratory copies exactly as read on 2026-08-25, the portal holding no copy of either, which is consistent with the fifth caution below, so this is one report out of three and I cannot tell from the outside whether the vendor posted an interim version before the remaining vials were appended or something else happened. I am recording the difference, not a reason for it. Second, the purity claim and the certificates disagree about method. The About page states that every batch is at least 99 percent pure, and across the 78 listings 62 repeat the same at least 99 percent figure bare while 10 attach a method to it in the spec line, HPLC, or HPLC and MS, Tesamorelin 10mg among them. The contradiction to record sits on those 10: the page promises an HPLC/MS certificate while the Janoshik reports themselves state no analytical method on their face. Third, the facility claims run wider than one page and nothing stands behind any of them: the "Manufactured in: GMP-certified facility" line appears on 10 listings, the BPC-157 page among them, and 8 further listings claim an ISO 9001:2015 and cGMP-audited facility, with no registrar, certificate number or facility named anywhere I looked, while the About page describes in-house production (0.22 micron filtration, ESI-MS structural confirmation, a 36-hour lyophilization cycle) and the Janoshik reports list the manufacturer as "AMP". Fourth, three of the four Support links in the site footer are dead: /privacy-policy/, /return-and-refund-policy/ and /shipping-and-delivery-policy/ each return HTTP 404 and only the Terms and Conditions resolve, so the only refund and shipping terms a buyer can actually read are inside those Terms, which state "all sales are final", no returns or exchanges, and a 48-hour window from delivery to report a damaged or incorrect item. The missing privacy policy is load-bearing: the entry-gate attestation asks the visitor to agree to it, and section 10 of the Terms points at the same absent page. The gate also asks the visitor to affirm 21 or over while section 2 of those Terms sets eligibility at 18 or over. The Terms name New Mexico as the governing law while the published entity address is in Arkansas. Fifth, the testing portal is populated for many current batches and most product pages link their own panel directly, so what follows is specific to the benchmark listing rather than general. The most prominent lab-report control on the AMP-3P 10mg page links the April batch, SKU AMP-3p1004012026-02, and its portal page answers with a notice that nothing has been published for that batch; the lookup is case sensitive and the uppercase form answers identically. The June panel for that product is published, but reaching it means hand-editing the URL to the batch code in exact case, and the storefront SKU names a batch two generations behind the newest published report. That June panel is also the only four-assay panel I opened: the other populated panels carry one assay each, with sterility, endotoxins and heavy metals marked pending.
Sibling domain, resolved rather than inferred. ameanopeptides.net is not a separate storefront. On 2026-08-25 it answered HTTP 301 Moved Permanently with Location: https://ameanopeptides.com/, served through Cloudflare, and the followed response measured 469,036 bytes, the same length as a direct fetch of the .com homepage in the same session, and carried the same page title "Home - Ameano Peptides". Same length and same title is the claim rather than byte-for-byte identity, since about ten thousand bytes of per-request nonces differ between any two fetches of that page. The .net publishes no catalog, price, certificate or policy of its own and its apex is a redirect on every path probed, but it is not inert: a live partners subdomain and a live mail configuration sit outside that redirect, both recorded in the Ameano Peptides (.net) entry.
Reader reviews
No reader review of this supplier is published yet. Every review is read and checked against the record before it appears. Add a review.
Open this supplier
Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.